Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
1.33
USD
|
+0.76%
|
|
+3.91%
|
+131.30%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
27.37
|
296.5
|
906.3
|
284.6
|
147.5
|
342.2
|
-
|
-
|
Enterprise Value (EV)
1 |
27.37
|
296.5
|
906.3
|
284.6
|
147.5
|
342.2
|
342.2
|
342.2
|
P/E ratio
|
-
|
-5.9
x
|
-15.2
x
|
-3.42
x
|
-2.21
x
|
-5.78
x
|
-5.02
x
|
-6.05
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
6,957
x
|
-
|
-
|
24.4
x
|
-
|
-
|
16.6
x
|
EV / Revenue
|
-
|
6,957
x
|
-
|
-
|
24.4
x
|
-
|
-
|
16.6
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-19,746,746
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
52,625
|
162,026
|
199,186
|
218,887
|
256,502
|
257,325
|
-
|
-
|
Reference price
2 |
0.5200
|
1.830
|
4.550
|
1.300
|
0.5750
|
1.330
|
1.330
|
1.330
|
Announcement Date
|
3/27/20
|
3/18/21
|
2/25/22
|
2/28/23
|
4/16/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0426
|
-
|
-
|
6.036
|
-
|
-
|
20.57
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.16
|
-21.28
|
-58.03
|
-84.87
|
-65.53
|
-66.69
|
-72.56
|
-61.02
|
Operating Margin
|
-
|
-49,940.69%
|
-
|
-
|
-1,085.67%
|
-
|
-
|
-296.63%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-58.42
|
-81.35
|
-63.08
|
-66.69
|
-72.56
|
-61.02
|
Net income
1 |
-
|
-
|
-58.36
|
-81.35
|
-63.08
|
-66.69
|
-72.56
|
-61.02
|
Net margin
|
-
|
-
|
-
|
-
|
-1,045.03%
|
-
|
-
|
-296.63%
|
EPS
2 |
-
|
-0.3100
|
-0.3000
|
-0.3800
|
-0.2600
|
-0.2300
|
-0.2650
|
-0.2200
|
Free Cash Flow
|
-
|
-15.02
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-35,231.25%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/18/21
|
2/25/22
|
2/28/23
|
4/16/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.419
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-10.79
|
-14.57
|
-18.03
|
-19.56
|
-23.12
|
-24.15
|
-17.75
|
-23.73
|
-15.42
|
-11.52
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-812.19%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-10.81
|
-14.58
|
-18.02
|
-19.47
|
-21.92
|
-21.94
|
-16.5
|
-22.92
|
-14.16
|
-10.97
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-10.76
|
-14.58
|
-18.02
|
-19.47
|
-21.92
|
-21.94
|
-16.5
|
-22.92
|
-14.16
|
-10.97
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-773.01%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0500
|
-0.0700
|
-0.0900
|
-0.0900
|
-0.1000
|
-0.1000
|
-0.0700
|
-0.1000
|
-0.0600
|
-0.0300
|
-0.0633
|
-0.0667
|
-0.0633
|
-0.0700
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
2/25/22
|
5/6/22
|
8/5/22
|
11/8/22
|
2/28/23
|
5/5/23
|
8/21/23
|
11/9/23
|
4/16/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-15
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.03
|
0.31
|
-
|
4.46
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
719.92%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/18/21
|
2/25/22
|
2/28/23
|
4/16/24
|
-
|
-
|
-
|
Last Close Price
1.33
USD Average target price
6.667
USD Spread / Average Target +401.25% Consensus |
1st Jan change
|
Capi.
|
---|
| +131.30% | 340M | | +25.69% | 48.09B | | +46.90% | 40.62B | | -3.46% | 40.43B | | -6.20% | 28.36B | | +9.17% | 24.89B | | -20.42% | 19.01B | | +28.07% | 12.09B | | +0.17% | 11.88B | | -1.24% | 11.8B |
Other Biotechnology & Medical Research
|